PTC Therapeutics Inc., already at cross purposes with the US FDA over its re-filing of Translarna (ataluren) for nonsense-mutation Duchenne muscular dystrophy (DMD), apparently decided to take a chance on the drug-pricing controversy as well, paying $140m up front on March 16 to acquire all rights for Marathon Pharmaceuticals LLC's DMD drug Emflaza (deflazacort), the launch of which has been delayed by pricing pushback.
PTC execs said during a same-day investor call to outline the transaction and report fourth quarter earnings that the company...